arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

AbCellera Biologics Inc.

ABCL
$7.58 ▲ +1.04 (+15.90%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

AbCellera Biologics Inc. faces fundamental challenges with weakness in Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.3B
Dividend Yield
Revenue Growth 96.3%
Op. Margin None
ROIC -5.3%
FCF / Share $-0.12
Trailing P/E
Price / Book 2.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$8.31M
↑ +96.3%
Net Income Profit after all expenses
$-43.16M
↑ +5.4%
Operating Margin Operating profit as % of sales
-63.7%
↑ +78.0% 0th
FCF / Share Free cash flow per share
$-0.12
↓ -65.3%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability
1
Returns
30
Cash Quality
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 8 years · 27 quarters